Ulotaront

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 208070

CAS#: 1310426-33-5 (free base)

Description: Ulotaront, also known as SEP-363856, and SEP-856, is a TAAR1/5-HT1A agonist. Ulotaront interacts with a small, common set of conserved residues within the TAAR1 and 5HT1A ligand-binding domain. Ulotaront is a compound of high solubility, high permeability, and low binding to plasma proteins. Ulotaront metabolism is mediated via both NADPH-dependent and NADPH-independent pathways, with CYP2D6 as the major metabolizing enzyme. Ulotaront is a promising agent for the treatment of schizophrenia with an apparent benign safety profile, which might provide a much-needed new and different treatment option for various domains of schizophrenia.

Chemical Structure

img
Ulotaront
CAS# 1310426-33-5 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 208070
Name: Ulotaront
CAS#: 1310426-33-5 (free base)
Chemical Formula:
Exact Mass: 0.00
Molecular Weight: 0.000
Elemental Analysis:

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1310422-41-3 (HCl)   1310426-33-5 (free base)   2375116-24-6 (besylate)   2375116-27-9 (mesylate)    

Synonym: Ulotaront; SEP-856; SEP856; SEP 856; SEP-363856; SEP 363856; SEP363856;

IUPAC/Chemical Name: (S)-1-(4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine

InChi Key: ABDDQTDRAHXHOC-QMMMGPOBSA-N

InChi Code: InChI=1S/C9H13NOS/c1-10-6-8-9-7(2-4-11-8)3-5-12-9/h3,5,8,10H,2,4,6H2,1H3/t8-/m0/s1

SMILES Code: CNC[C@H]1C2=C(C=CS2)CCO1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Feemster JC, Westerland SM, Gossard TR, Steele TA, Timm PC, Jagielski JT, Strainis E, McCarter SJ, Hopkins SC, Koblan KS, St Louis EK. Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis. Sleep Med. 2023 Jan;101:578-586. doi: 10.1016/j.sleep.2022.11.022. Epub 2022 Nov 24. PMID: 36584503.


2: Højlund M, Correll CU. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia. Expert Opin Investig Drugs. 2022 Dec;31(12):1279-1290. doi: 10.1080/13543784.2022.2158811. Epub 2022 Dec 22. PMID: 36533396.


3: Saarinen M, Mantas I, Flais I, Ågren R, Sahlholm K, Millan MJ, Svenningsson P. Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP- 363856. Neuropsychopharmacology. 2022 Nov 29. doi: 10.1038/s41386-022-01504-0. Epub ahead of print. Erratum for: Neuropsychopharmacology. 2022 Dec;47(13):2319-2329. PMID: 36446929.


4: Rojas M, Chávez-Castillo M, Duran P, Ortega Á, Bautista-Sandoval MJ, Salazar J, Riaño-Garzón M, Chacín M, Medina-Ortiz O, Palmar J, Cudris-Torres L, Bermúdez V. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. Curr Pharm Des. 2022;28(33):2725-2741. doi: 10.2174/1381612828666220428102802. PMID: 36321314.


5: Kane JM. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia. J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5 Suppl 1):S1-S13. doi: 10.1097/JCP.0000000000001596. PMID: 36099402.


6: Kwan C, Huot P. An overview of the active clinical trials for Parkinson's disease psychosis. Neurodegener Dis Manag. 2022 Aug;12(4):165-170. doi: 10.2217/nmt-2022-0020. Epub 2022 May 20. PMID: 35592949.


7: Ren X, Xiong J, Liang L, Chen Y, Zhang G. The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice. Molecules. 2022 Apr 25;27(9):2755. doi: 10.3390/molecules27092755. PMID: 35566106; PMCID: PMC9105920.


8: Xiao G, Chen YL, Dedic N, Xie L, Koblan KS, Galluppi GR. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia. Pharm Res. 2022 May;39(5):837-850. doi: 10.1007/s11095-022-03267-1. Epub 2022 Apr 28. PMID: 35484370; PMCID: PMC9160101.


9: Sparacino G, Verdolini N, Vieta E, Pacchiarotti I. Existing and emerging pharmacological approaches to the treatment of mania: A critical overview. Transl Psychiatry. 2022 Apr 23;12(1):169. doi: 10.1038/s41398-022-01928-8. PMID: 35461339; PMCID: PMC9035148.


10: Liang L, Ren X, Xu J, Ma Y, Xue Y, Zhuang T, Zhang G. Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia. Molecules. 2022 Apr 14;27(8):2550. doi: 10.3390/molecules27082550. PMID: 35458749; PMCID: PMC9024832.


11: Correll CU, Abi-Dargham A, Howes O. Emerging Treatments in Schizophrenia. J Clin Psychiatry. 2022 Feb 15;83(1):SU21204IP1. doi: 10.4088/JCP.SU21204IP1. PMID: 35172048.


12: Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, Campbell JE, Dedic N, Hopkins SC, Koblan KS, Xie L. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. ACS Med Chem Lett. 2021 Dec 6;13(1):92-98. doi: 10.1021/acsmedchemlett.1c00527. PMID: 35047111; PMCID: PMC8762745.


13: Synan C, Bowen C, Heal DJ, Froger-Colléaux C, Beardsley PM, Dedic N, Hopkins SC, Campbell U, Koblan KS. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend. 2022 Feb 1;231:109261. doi: 10.1016/j.drugalcdep.2021.109261. Epub 2021 Dec 31. PMID: 35033729.


14: Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. Int J Mol Sci. 2021 Dec 7;22(24):13185. doi: 10.3390/ijms222413185. PMID: 34947997; PMCID: PMC8704992.


15: Correll CU, Koblan KS, Hopkins SC, Li Y, Heather Dworak, Goldman R, Loebel A. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021 Dec 9;7(1):63. doi: 10.1038/s41537-021-00190-z. PMID: 34887427; PMCID: PMC8660889.


16: Spoelstra SK, Bruggeman R, Knegtering H. Een antipsychoticum zonder dopamine­receptorblokkade? [An antipsychotic without dopamine receptor blockade?]. Tijdschr Psychiatr. 2021;63(11):804-809. Dutch. PMID: 34851520.


17: Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. New Antipsychotic Medications in the Last Decade. Curr Psychiatry Rep. 2021 Nov 29;23(12):87. doi: 10.1007/s11920-021-01298-w. PMID: 34843030.


18: Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022 Jan;132:324-361. doi: 10.1016/j.neubiorev.2021.11.032. Epub 2021 Nov 24. PMID: 34838528.


19: Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9. PMID: 34751928; PMCID: PMC8626367.


20: Chen YL, Shi Y, LaFayette A, Shi L, Koblan KS, Galluppi GR. A sensitive LC- MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study. J Pharm Biomed Anal. 2022 Jan 5;207:114404. doi: 10.1016/j.jpba.2021.114404. Epub 2021 Oct 6. PMID: 34700199.